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Abstract
Background: Hepatitis B virus-related liver fibrosis (HBV-LF) always progresses from inflammation to fibrosis. However, the
relationship between these two pathological conditions is not fully understood. Here, it is postulated that the balance
between regulatory T (Treg) cells and T helper 17 (Th17) cells as an indicator of inflammation may predict fibrosis
progression of HBV-LF.
Methodology/Principal Findings: The frequencies and phenotypes of peripheral Treg and Th17 cells of seventy-seven
HBeAg-positive chronic hepatitis B (CHB) patients who underwent liver biopsies and thirty healthy controls were
determined by flow cytometry. In the periphery of CHB patients, both Treg and Th17 frequencies were significantly
increased and correlated, and a lower Treg/Th17 ratio always indicated more liver injury and fibrosis progression. To
investigate exact effects of Treg and Th17 cells during HBV-LF, a series of in vitro experiments were performed using purified
CD4
+, CD4
+CD25
+, or CD4
+CD25
2 cells from the periphery, primary human hepatic stellate cells (HSCs) isolated from healthy
liver specimens, human recombinant interleukin (IL)-17 cytokine, anti-IL-17 antibody and HBcAg. In response to HBcAg,
CD4
+CD25
+ cells significantly inhibited cell proliferation and cytokine production (especially IL-17 and IL-22) by CD4
+CD25
2
cells in cell-contact and dose-dependent manners. In addition, CD4
+ cells from CHB patients, compared to those from HC
subjects, dramatically promoted proliferation and activation of human HSCs. Moreover, in a dramatically dose-dependent
manner, CD4
+CD25
+ cells from CHB patients inhibited, whereas recombinant IL-17 response promoted the proliferation and
activation of HSCs. Finally, in vivo evidence about effects of Treg/Th17 balance during liver fibrosis was obtained in
concanavalin A-induced mouse fibrosis models via depletion of CD25
+ or IL-17
+ cells, and it’s observed that CD25 depletion
promoted, whereas IL-17 depletion, alleviated liver injury and fibrosis progression.
Conclusions/Significance: The Treg/Th17 balance might influence fibrosis progression in HBV-LF via increase of liver injury
and promotion of HSCs activation.
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Introduction
Worldwide, hepatitis B virus (HBV) affects over 350 million
individuals and continues to cause more than a million deaths
annually from end-stage liver diseases [1].Although HBV itself is
noncytopathic, it causes chronic immune-induced liver injury and
forces disease progression from mild inflammation, to severe
inflammation, to fibrosis, and finally to cirrhosis. Despite the close
association of inflammation with fibrosis in HBV-related liver
fibrosis (HBV-LF), little is known about cellular cross-talks
between these two pathways.
Many mechanisms have been proposed for impaired virus-
specific T cell responses during chronic HBV infection. One
possible mechanism is induction of host-mediated regulatory
mechanisms after exposure to HBV-related antigens. The most
recent concerns regulatory T (Treg) cells, a subset of CD4
+ cells
suppressing immune responses to maintain unresponsiveness to
self-antigens and prevent excessive immune responses to foreign
antigens, which play an important role in autoimmune and
infectious diseases [2]. These cells can be generated in the
thymus as naturally-occurred Treg or in the periphery as induced
Treg. Different populations of Treg cells have also been reported
on the basis of high expression of CD25 and forkhead family
transcription factor 3 (Foxp3) or on the basis of the production of
immunosuppressive cytokines, such as interleukin (IL)-10 or
transforming growth factor (TGF)-b [2]. CD4
+CD25
+Foxp3
+
cells are the most characterized Treg cells. Although these Treg
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lymphocyte antigen 4 (CTLA-4)/CD152, CD45RO and gluco-
corticoid-induced tumor necrosis factor-related protein (GITR),
Foxp3 has been demonstrated to be a unique marker. In
humans, CD4
+CD25
+Foxp3
+ cells represent 3–10% of total
CD4
+ cells in peripheral blood [3]. CD4
+CD25
+Foxp3
+ cells
have recently been reported to increase in chronic hepatitis B
(CHB) patients, which could inhibit HBV-specific CD8
+ T cell
response and show a close association with HBV loads and
serum alanine aminotransferase (ALT) levels [4–6]. Here, we
suppose Treg cells to be a ‘dual-edged’ sword during chronic
HBV infection for being detrimental to facilitate HBV escape
and being protective to prevent immune-mediated liver injury.
Recent researches on Treg cells have turned attention to their
interactions with other effector cells because their balance
determines the outcome of immune and inflammation. Interest-
ingly, T helper 17 (Th17) cells, another newly identified subset of
CD4
+ cells with retinoid orphan nuclear receptor c t (RORct) as
the specific transcriptional factor, are closely-linked with Treg cells
and have also been implicated in autoimmune and infectious
diseases [7]. On development pathways, both induced Treg and
Th17 cells require TGF-b. Moreover, retinoic acid (RA) and IL-2
promote the development of Treg cells and inhibit that of Th17
cells, whereas IL-6, IL-21 and IL-23 facilitate the development of
Th17 cells and inhibit that of Treg cells [8]. On immune function,
in contrast to the regulatory features of Treg cells, Th17 cells
mediate strong inflammation by producing a cocktail of cytokines
such as IL-17, IL-17F, IL-21, IL-22, IL-6, and tumor necrosis
factor-a (TNF-a), of which IL-17 has been characterized as
a major effector cytokine [7]. Increase of Th17 cells have also been
observed in CHB patients to inhibit HBV replication and cause
immune-mediated liver injury [9–10]. Accumulating data suggest
the plasticity of Treg and Th17 cells under certain cytokine
conditions. For example, Treg cells can be converted to IL-17-
expressing cells in response to IL-6 and IL-21 whereas Th17 cells
can give a rise to Th1 or Th2 cells in the presence of IL-12 or IL-4,
respectively [11]. Thus, we suggest the balance (or interplay)
between Treg and Th17 cells might be a crucial indicator of
immune homeostasis that can partly reflect the balance between
pro-inflammation and anti-inflammation. The Treg/Th17 bal-
ance has already been reported to skew in several autoimmune
and inflammatory diseases such as primary biliary cirrhosis and
rheumatoid arthritis [12,13]. Also, Treg/Th17 balance has been
described to change in CHB patients undergoing treatment with
entecavir [10] or end-stage liver failure [14]. However, whether
and how this balance influences disease progression of HBV-LF
has not been determined.
Hepatic stellate cells (HSCs), located in the space of Disse, are
the cornerstone of liver fibrosis [15]. In response to inflammatory
stimuli, quiescent HSCs usually activate and transform into
myfibroblast-like cells and produce abundant cytokines and
extracellular matrix (ECM). Besides, activated HSCs secret
matrix metalloproteinases (MMPs) to degrade ECM and also
synthesize tissue inhibitors of metalloproteinases (TIMPs) to
control the enzyme activity of MMPs. Thus, to some extent, the
functional status of HSCs determines whether liver fibrosis
progresses or regresses. Collectively, to estimate whether a factor
is protective or detrimental during liver fibrosis, researches could
be started by getting a preliminary picture from in vitro co-
culture/stimulation experiments with HSCs. Interestingly, HSCs
are no longer bystanders of inflammation, and are recently
reported to have various immune functions. Under inflammatory
circumstances, activated HSCs can behave as antigen presenting
cells and elicit T cell proliferation [16,17], which requires direct
contacts between T cells and HSCs. Moreover, additional
expression of programmed cell death ligand 1 (PD-L1) endows
HSCs with the immune regulatory property to induce T cell
apoptosis [18,19]. This dual roles of HSCs as both fibrotic and
inflammatory participants make their interplay with other
immune cells as a perfect cut-in point to investigate potential
cellular cross-talks between inflammation and fibrosis [20]. HBV-
LF is essentially an immune and inflammatory process. However,
whether and how immune cells such as Treg and Th17 cells
influence fibrosis progression is unclear.
Here, we designed this study to determine the Treg/Th17
balance in CHB patients, and to ascertain whether this balance
influences fibrosis progression of HBV-LF on their influence on
HBV replication, immune-mediated liver injury, and HSCs
activation.
Methods
Patients
Seventy-seven CHB patients who underwent liver biopsies at
Zhongshan Hospital (Shanghai, China) and thirty healthy controls
(HC) were enrolled. All patients were seropositive for hepatitis B
surface antigen (HBsAg) and hepatitis B e antigen (HBeAg), and
were diagnosed according to criteria previously described [21].
Patients with other viral infections, fatty liver diseases or
autoimmune liver diseases were excluded. None of these patients
had received anti-viral or immunomodulatory therapy before
sampling. The serum HBV loads were detected by a virological
assay (detection limit: 500 copies/mL) previously described [10].
The inflammation grades (G stands for inflammation) and fibrosis
stages (S stands for fibrosis) of liver biopsies were determined by
two senior clinical pathologists using a modified Scheuer scoring
system [22]. The study protocol was approved by the Research
Ethics Committee of Zhongshan Hospital (No. 2010-87) and
written informed consent was obtained from each subject. The
clinical characteristics of all subjects are listed in Table 1. To
investigate how Treg and Th17 cells involve in CHB pathogenesis,
CHB patients were further divided into several subgroups
according to their levels of liver injury or HBV replication, or
fibrosis progression to be analyzed. First, patients with the serum
HBV load of 10
5–10
7 copies/mL (n=57) were divided into three
subgroups according to the serum ALT level: , upper limit of
normal (ULN) (n=7), ULN–2ULN (n=15) and .2ULN (n=35).
Second, patients with the normal ALT (n=13) were divided into
two subgroups according to the HBV load: 10
5–10
7 copies/mL
(n=7) and .10
7 copies/mL (n=6). Third, patients with the
inflammation grade of G2–3 (n=56) were divided into the
following two subgroups according to the fibrosis stage (S score):
S0–2 (n=21) and S3–4 (n=35). Also, to dissect the association of
the Treg/Th17 ratio with degree of hepatic inflammation, CHB
patients with fibrosis stages of S0–1 (n=15) were divided into two
subgroups according to their inflammation grades (G score): G1
(n=6) and G2–3 (n=9).
Mouse Liver Fibrosis Models
Eight-week-old female BALB/c mice weighing around 18 g
were obtained from the Shanghai Laboratory Animal Centre
(Chinese Academy of Science, Shanghai, China), maintained
under specific pathogen-free conditions and used for concanavalin
A (ConA) induced fibrosis models. Liver fibrosis (ten mice in each
group) was induced by intravenous (i.v.) injection with ConA
(Sigma-Aldrich, Tokyo, Japan) dissolved in pyrogen-free phos-
phate buffered saline (PBS) at a dose of 10 mg/kg body weight
once a week for up to 4 weeks [23,24]. Control mice were injected
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liver specimens were collected at week 1, 2, 3 and 4 after ConA
administration for analyses. Liver injury was determined by
measuring serum ALT levels using a commercially available ALT
Reagent Kit (Rongsheng Biotech, Shanghai, China). For histo-
pathologic analyses, 4 mm-thick sections of paraffin-embedded and
formalin-fixed liver specimens were stained with Masson to
determine the collagen fibers. Each assay was performed in
triplicate. The experimental procedures conformed to the guide-
lines outlined in the Guide for the Care and Use of Laboratory
Animals and were approved by the Research Ethics Committee of
Zhongshan Hospital (No. 2010-87).
Preparation of Peripheral Blood Mononuclear Cells
Peripheral blood mononuclear cells were isolated from hepa-
rinized blood samples using Ficoll-Paque PLUS (GE Healthcare,
Piscataway, NJ, USA). Cells were cultured in RPMI 1640 medium
(Gibco, Grand Island, NY, USA) containing 10% fetal calf serum
(FCS, Gibco). IL-2 (300 U/mL, PeproTech, Rocky Hill, NJ, USA)
was added to enable survival of the lymphocytes in vitro.
Preparation of Non-parenchymal Cells from Mouse Livers
and Spleens
For the preparation of non-parenchymal liver cells, the
abdominal cavities of anesthetized mice were opened and the
livers were perfused through the portal vein for 5 min with Hank’s
balanced salt solution (HBSS), 4 min with 0.5 mg/mL pronase
solution, and 4 min with 0.25 mg/mL collagenase IV solution at
a flow rate of 6 mL/min [17]. The liver tissue was then minced
and further digested in 50 mL HBSS supplemented with 50 mg
collagenase IV, 50 mg pronase, and 1 mg DNase (20 min, 37uC).
The resulting cell suspension was passed through a 100 mm nylon
mesh filter and then centrifuged at 300 g (10 min, 4uC). The cell
pellets were resuspended in 8 mL 40% Percoll solution and then
carefully overlaid on 5 mL of 70% Percoll solution (Sigma-
Aldrich, St. Louis, MO, USA). After centrifugation at 450 g
(17 min, 4uC), the layer of cells at the intermediate interface was
harvested as target cells. Spleen cells were isolated following
mechanical disruption of the spleen and erythrocyte lysis as
described elsewhere [25].
Purification of Human CD4
+, CD4
+CD25
+ and
CD4
+CD25
2 Cells
When sufficient PBMCs could be obtained from G2–3S3–
4 CHB patients, they were chosen for further purification. CD4
+,
CD4
+CD25
+ and CD4
+CD25
2 cells were purified using a fluo-
rescence activated cell sorting (FACS) Aria cell sorter (Becton
Dickinson, Palo Alto, CA, USA) after the staining with anti-CD4-
fluorescein isothiocyanate (FITC) and/or anti-CD25-phycoery-
thrin (PE) antibodies. The purity of isolated cells was .90%
(shown in Figure S1). Blood samples were obtained from CHB
patients and their age-and-sex matched HC subjects. Co-cultures
were performed with human leukocyte antigen (HLA)-compatible
(HLA-identical, cells from the same individual) or incompatible
(Allogenic, cells from the same species but different individuals)
cells.
Preparation of Human Hepatic Stellate Cells
Human HSCs were obtained from liver specimens of patients
with liver hemangiomas who had undergone surgical resections.
This material was used in accordance with the guidelines of the
local Ethics Committee. HSCs were isolated using methods
previously described [16]. They were cultured at a concentration
of 1610
5 cells per well in high glucose Dulbecco’s modified Eagle’s
medium (DMEM, Gibco) containing 20% FCS for 1–2 (quies-
cent), 3–5 (intermediate), or 7–10 (activated) days as described
elsewhere [18,26]. Cell viability was greater than 90% as
determined by trypan blue exclusion. The purity of HSCs ranged
from 90% to 95% as determined by glial fibrillary acidic protein
(GFAP) staining (shown in Figure S2) and the typical microscopic
appearance of the lipid droplets. On days 1–2, isolated HSCs were
quiescent, round, had abundant lipid droplets, and lacked a-
smooth muscle actin (a-SMA) expression. At day 7, the cells
become activated and begin to express a-SMA (shown in Figure
S2). Cells from days 3–5, which have an intermediate appearance,
were chosen for in vitro analyses in this study.
T-cell Proliferation Assay
Purified CD4
+CD25
2 cells were cultured in triplicate in
a concentration of 1610
5 cells per well in 100 mL RPMI 1640
medium containing 10% FCS. The cells were stimulated with or
without 1 mg/mL HBcAg (ProSpec, East Brunswick, NJ, USA)
and cultured for 6 days. Inhibition of CD4
+CD25
+ cells on cell
proliferation and cytokine production of CD4
+CD25
2 cells was
tested by directly adding 10% (11,000 cells), 20% (25,000 cells), or
30% (43,000 cells) CD4
+CD25
+ cells to 1610
5 CD4
+CD25
2 cells
as described elsewhere [4]. After 5 days of incubation, 50 mLo f
supernatant was harvested for analysis. Cell proliferation was
measured by the thymidine method, and converted to a stimulation
index as the mean number of counts per minute (cpm) for cells
exposed to antigen divided by the mean number of cpm for cells
not exposed to antigen.
Cell Co-cultures
Using a HTS transwell-96 co-culture system (Corning, Corning,
NY, USA), in which a polycarbonate membrane with a pore-size
of 0.4 mm is set between upper and lower compartments to
prevent direct cell contacts. Cells of different types can be adding
to the same compartment or different compartments for contact or
non-contact co-cultures. 1 mg/mL HBcAg was always added in
each well during the co-cultures to provide specific antigen
stimulation during HBV-LF in vitro.
Table 1. Clinical characteristics of all subjects.
Healthy controls Chronic hepatitis B
Case 30 77
Age (years) 32 (25–47) 39 (30–49)
Sex (M/F) 23/7 60/17
AST (U/L) 45 (30–60) 152 (62–320)
ALT (U/L) 39 (24–58) 198 (55–560)
TBIL (mmol/L) 10 (4–18) 19 (13–32)
PT (s) NA 12 (10–13)
ALB (g/L) 48(40–54) 40 (35–45)
HBV DNA (copies/mL) NA 2610
6 (1610
526610
8)
Data are shown as median and range. AST, aspartate aminotransferase; ALT,
alanine aminotransferase; TBIL, total bilirubin; PT, prothrombin time; ALB,
albumin; NA, not applicable.
doi:10.1371/journal.pone.0039307.t001
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T-cell cytokines (IL-10, TGF-b, IL-17, IL-21, IL-22 and TNF-
a) in serum samples, or in the supernatant of in vitro cultures were
measured using enzyme-linked immunosorbent assay (ELISA) kits
(R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions. The concentrations of cytokines
(TGF-b, platelet derived growth factor [PDGF]-BB, connective
tissue growth factor [CTGF] and epidermal growth factor [EGF])
principally produced by activated HSCs in the supernatant of
in vitro cultures were also evaluated by ELISA kits (R&D Systems).
Hepatic Stellate Cells Proliferation Assay
HSCs were directly co-cultured with human CD4
+,
CD4
+CD25
+ and CD4
+CD25
2 cells from age-and-sex matched
HC and CHB subjects or incubated with human recombinant
cytokine IL-17 (PeproTech) at various concentrations (1, 3, 5 ng/
mL) for 6 days. Cell proliferation of HSCs was monitored by
a Cell-IQ system (Chipman Technologies, Tampere, Finland),
which is a live cell imaging and analysis platform. Cell-IQ
automatically recognizes cell type and records corresponding cell
number every 15 minutes. Four high-power fields (hpf, 4006mag-
nification) per well were chosen for consecutive cell monitoring
and proliferation analysis. The cell proliferation rate was
calculated using the following formula: (mean cell number in
each hpf after incubation with stimulants)/(mean cell number in
each hpf before incubation)6100%21.
Flow Cytometry
All antibodies used in flow cytometry were purchased from
eBioscience (San Diego, CA, USA), with the exception of PE-
conjugated anti-human TGF-b1, 2 and 3 (R&D Systems). For the
staining of intracellular cytokines including IL-17, TGF-b and IL-
10, cells were stimulated with phorbol-12-myristate-13-acetate
(PMA, 25 ng/mL, Enzo, New York, NY, USA) and ionomycin
(1 mg/mL, Enzo) in 1 mL RPMI 1640 medium supplemented
with 10% FCS at 37uC for 6 hours. Brefeldin A (1 mg/mL, Enzo)
was added 1 hour prior to cell harvesting. After labeling with
surface antibodies, cells were permeabilized with a fix/perm
solution (eBioscience) and stained with the appropriate intracel-
lular antibodies according to the manufacturer’s instructions.
Isotype-matched control antibodies were used to determine the
level of background staining and help set a gate. Stained cells were
analyzed by FACSCalibur (Becton Dickinson) and FlowJo
software 7.6.1 (Tristar, El Segundo, CA, USA).
Western Blot Analysis
HSCs were collected as adherent cells after the co-cultures with
CD4
+, CD4
+CD25
+ or CD4
+CD25
2 cells from age-and-sex
matched HC and CHB subjects or the incubations with various
concentrations of human recombinant IL-17 for 3 days. Cell lysis,
protein extraction and western blot analysis were performed as
described elsewhere [27]. Detection of a-SMA proteins was
performed with a rabbit anti-human a-SMA polyclonal antibody
(1:400; Ab5694). Protein loading was normalized using a HRP-
conjugated anti-GAPDH antibody (1:10,000; KC5G5, CHN).
The ratio of a-SMA to GAPDH was calculated as the relative
quantification.
In Vivo Administration of Neutralizing Antibodies
To deplete CD25
+ cells in vivo, one day before and after the
administration of PBS (controls) or ConA, BALB/c mice were
intraperitoneally (i.p.) injected with anti-mouse-CD25 monoclonal
antibody (mAb, clone PC61.5.3, rat IgG1, American Type
Culture Collection, 0.5 mg/mouse) [28,29]. To deplete IL-17
+
cells in vivo, anti-IL-17 mAb (Clone 50104, rat IgG2a, R&D
Systems, 100 mg/mouse) was also i.p. injected twice a week for up
to 4 weeks [30,31]. Control mice were i.p. injected with control rat
IgG (R&D Systems). Cell depletion was confirmed weekly by flow
cytometry one day after the second administration of mAb, which
always resulted in .90% cell depletion.
Quantitative Reverse Transcriptase-polymerase Chain
Reaction (qRT-PCR)
Mice were scarificed at week four after ConA administration.
Their livers were dissected, immediately frozen in liquid nitrogen,
and stored at 280uC. Total RNA was extracted using TRIzol
(Invitrogen, Carlsbad, CA, USA). Following the manufacturer’s
instructions, reverse transcription was performed using a Prime-
Script RT reagent kit with gDNA Eraser (Takara, Beijing, China)
and quantitative real-time PCR conducted with a SYBR RT-PCR
Kit (Takara) using the following conditions: 30 seconds at 95uC,
followed by a total of 40 two-temperature cycles (5 seconds at
95uC and 30 seconds at 60uC). Each assay was performed in
triplicate. For analysis, the expression of target genes was
normalized by the housekeeping gene GAPDH. Based on the
DDCt method, relative amounts of mRNA were expressed as
2
2DDCt. The primer sequences used were as follows: GAPDH
sense 59-TGTGTCCGTCGTGGATCTGA-39; GAPDH anti-
sense 59-TTGCTGT TGAAGTCGCAGGAG-39; collagen type
I alpha 1 (COL1a1) sense 59-TGCTGGCCCCAAG GGTCCTT-
39; COL1a1 antisense 59-GGCTGCCAGGACTGCCA GTG-39;
collagen type III alpha 1(COL3a1) sense 59-CTTAGAAGCT-
GATGGGATC-39; COL3a1 antisense 59-TTGCCTTGCGTG
TTTGT-39; TGF-b1 sense 59-GTGTGGAGCAACATGTG-
GAAC TCTA-39; TGF-b1 antisense 59-TTGGTTCAGC-
CACTGCCGTA-39; a-SMA sense 59-AAGAG CATCCGA-
CACTGCTGAC-39; a-SMA antisense 59-
AGCACAGCCTGAATAGCCACATAC-39; PDGF-BB sense
59-GAGATT GTGCGAAAGAAGCC-39; PDGF-BB antisense
59-CTTCTAGTCACAGGCCGAGG-39.
Statistical Analysis
Results are presented as mean 6 standard error of the mean
(SEM), in triplicate. Statistical analyses were performed using the
GraphPad Software Version 5.01 (CA, USA). Student’s t-test, one-
way ANOVA, x
2 test and Pearson’s rank correlation were
performed as appropriate, and p values of less than 0.05 (two-
tailed) were considered statistically significant.
Results
Phenotypes of Treg and Th17 Cells in the Periphery of
CHB Patients
We characterized CD4
+CD25
+Foxp3
+ and CD4
+IL-17
+ cells
respectively as Treg and Th17 cells, (Figure1A), and determined
their ratios in total CD4
+ cells as the frequencies. The isotype
controls were also shown (Figure 1B). We selectively determined
the co-expression of membrane-bound inhibitory molecule
CTLA-4, and inhibitory cytokines IL-10 and TGF-b in Treg
cells from CHB patients (Figure 1C). Treg cells from CHB
patients expressed significantly more CTLA-4 than did those
from HC subjects (Figure 1E). However, Treg cells whether from
CHB patients or HC subjects barely secreted any IL-10 or TGF-
b. We also determined the co-expression of chemokine receptor-
6 (CCR6, home receptor), IFN-c and Foxp3 in Th17 cells.
Results were that in CHB patients, a plurality of Th17 cells
(32%–72%, n=20) co-expressed CCR6, whereas much less of
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found that the frequency of CD4
+IL-17
+Foxp3
+ cells significantly
increased in CHB patients (Figure 1F).
Treg and Th17 Cells Involved in Fibrosis Progression of
HBV-LF
We determined the frequencies of Treg and Th17 cells in the
periphery of 30 HC subjects and 77 CHB patients by flow
cytometry. Compared to HC subjects, both Treg and Th17 cell
frequencies significantly increased in CHB patients (Figure 2A).
Next, we analyzed Treg and Th17 cell frequencies in differently-
classified CHB subgroups, and found in CHB patients: with
increased ALT levels, Treg frequency down-regulated whereas
Th17 frequency up-regulated, both significantly (Figure 2B); with
increased HBV loads, we observed a significant increase of Treg
frequency but no change of Th17 frequency (Figure 2C); and with
increased S scores, we detected a decrease of Treg frequency and
an increase of Th17 frequency both in dramatic amplitudes
(Figure 2D).
Peripheral Treg/Th17 Ratios Indicated Liver Injury and
Fibrosis Progression of HBV-LF
Regulatory Treg and Th17 cells have been reportedly closely-
linked [4,7,8]. Here we first performed the Pearson’s rank
correlation between peripheral Treg and Th17 frequencies of
CHB patients (n=77) and found these two cell lineages were
significantly correlated (r=0.5657, p,0.0001) (Figure 3A), sug-
gesting the existence of Treg/Th17 balance in CHB patients. We
then calculated the Treg/Th17 ratios using the frequencies and
found that the ratios of CHB patients were dramatically higher
than those of HC subjects. However, in CHB subgroups, the ratios
significantly decreased whether with enhanced G scores (Figure 3B)
or increased ALT levels (Figure 3C) or with advanced S scores
(Figure 3D). The ratios did not change dramatically with elevated
virus loads (data not shown).
Treg Cells Regulated Th17 Response in HBV-LF
We determined lineage-associated cytokines of Treg and Th17
cells in the serum of CHB patients and HC subjects, and found
the concentrations of IL-17, IL-21 and IL-22 significantly
Figure 1. Phenotypes of Treg and Th17 cells in the periphery of CHB patients. (A, B) Representative dot plots of peripheral Treg and Th17
cells with matched-isotype controls. (C) Representative co-expressions of CTLA-4, IL-10 and TGF-b in Treg cells of CHB patients. (D) Representative co-
expressions of CCR6, IFN-c and Foxp3 in Th17 cells of CHB patients. (E) The frequencies of CD4
+CD25
+Foxp3
+CTLA-4
+ cells are significantly higher in
CHB patients (n=28) than in HC subjects (n=10). (F) The frequencies of CD4
+Foxp3
+IL-17
+ cells are significantly higher in CHB patients (n=29) than
in HC subjects (n=9). Data in subfigures D–E are presented as each value and the mean value. ***, p,0.001.
doi:10.1371/journal.pone.0039307.g001
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panel) cells in age-and-sex matched HC and CHB subjects. (B) Subgroup analyses were performed in CHB patients with similar HBV loads (10
5–10
7
copies/mL) but with differing ALT levels (n=57). With elevated ALT levels, Treg frequency decreased significantly whereas Th17 increased
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similar in both groups (Figure 4A). In addition, in response to
HBcAg, CD4
+ cells from CHB patients showed a significantly
enhanced ability to secret Th17-associated cytokines, including
IL-17, IL-21, IL-22 and TNF-a (Figure 4B). Although both Treg
and Th17 responses involved in CHB pathogenesis, the above
results suggested that Treg cells might be independent of
cytokines whereas Th17 cells mainly depended on cytokines.
Because Foxp3 staining requires cell membrane permeablization
and impairs cell function, CD4
+CD25
+ cells are used to
represent Treg response to perform following in vitro experiments
as described elsewhere [4–6]. To investigate the influence of
Treg cells on Th17 response during HBV-LF, with the adding of
1 mg/mL HBcAg during co-cultures, CD4
+CD25
+ cells (2.5610
4
cells/well) from CHB patients (n=6) were co-cultured with HLA-
identical CD4
+CD25
2 cells (1610
5/well) in both contact and
non-contact manners for 5 days at a cell ratio of 1:4, and Th17
associated cytokines in the supernatant were determined by
ELISA. We found the CD4
+CD25
+ cells from CHB patients
could significantly down-regulate the concentrations of IL-17 and
IL-22 in the co-culture systems, which were probably produced
by Th17 cells existing in CD4
+CD25
2 cells, and this effect was
only observed when the co-cultures were performed in contact
manner (Figure 4C). Therefore, we performed subsequent co-
cultures only in contact manner. Next, also with 1 mg/
ml HBcAg, the inhibition of CD4
+CD25
+ cells on Th17 response
was performed by directly adding 0, 10% (11,000/well), 20%
(25,000/well), or 30% (43,000/well) CD4
+CD25
+ cells from
CHB patients (n=6) to HLA-identical CD4
+CD25
2 cells
(1610
5/well) and the contact co-cultures were performed for 6
days. We found that CD4
+CD25
+ cells from CHB patients
dramatically inhibited IL-17 and IL-22 production by
CD4
+CD25
2 cells (Figure 4D) and the proliferation of
CD4
+CD25
2 cells both in dose dependent manners (Figure 4E).
We also performed some co-cultures of CD4
+CD25
2 cells
(1610
5/well) from CHB patients together with HLA-identical
CD4
+CD25
+ cells or allogenic CD4
+CD25
+ cells (25,000/well)
from other CHB patients or age-and-sex matched HC subjects
(n=6). We also determined the number of Foxp3
+ cells among
different groups of CD4
+CD25
+ cells by flowcytometry, and
found that containing almost the same number of Foxp3
+ cells,
HLA-identical CD4
+CD25
+ cells showed the most enhanced
ability to inhibit the proliferation of CHB-CD4
+CD25
2 cells in
response to HBcAg (Figure 4F).
CD4
+ Cells During HBV-LF Promoted Activation and
Proliferation of Primary HSCs
Over the decade, activation of HSCs has always been the
cornerstone of liver fibrosis [15]. Activated HSCs usually pro-
liferate more dramatically than their quiescent forms. Here, to
investigate the influence of CD4
+ cells on HSCs during HBV-LF,
we first performed contact co-cultures of primary HSCs (1610
5/
well) in intermediate state respectively with CD4
+ cells (1610
4/
well) from age-and-sex matched CHB and HC subjects (n=6) for
6 days. We consecutively monitored cell proliferation of HSCs
with the Cell-IQ (Figure 5A) and assessed HSC-sourced growth
factors (TGF-b, PDGF-BB, CTGF and EGF) in the supernatant at
the end of the co-cultures via ELISA. Data indicated that,
compared to HC subjects, CD4
+ cells from CHB patients
dramatically promoted cell proliferation (Figure 5B) and growth
factors production of HSCs (Figure 5C). Also, by western blot, we
determined a-SMA proteins in adherent cells, as differently-
cultured HSCs, at the end of co-cultures. We found CD4
+ cells
from CHB patients promoted, whereas those from HC subjects
barely regulated a-SMA proteins in HSCs (Figure 5D).
Treg and Th17 Responses During HBV-LF Differently
Regulated Primary HSCs in Vitro
Since no reliable surface markers have been identified for
Th17 cells yet, we used recombinant IL-17 (PeproTech) cytokine
to partially represent Th17 response in our study. To detect
influence of Th17 response on HSCs during HBV-LF, we
cultured HSCs (1610
5/well) in contact manner with
CD4
+CD25
2 cells (1610
4/well) from CHB patients (n=6) with
or without adding anti-IL-17 antibody (10 mg/mL) and recom-
binant IL-17 at various concentrations (1, 3, 5 ng/mL) for 6
days. Results indicated that Th17 response of CHB patients
enhanced cell proliferation and PDGF-BB production of HSCs
both in dose-dependent manners (Figure 6A&B). We then co-
cultured HSCs (1610
5/well) respectively with CD4
+CD25
2 cells
(1610
4/well) from age-and-sex matched HC and CHB subjects
(n=6), also with the addition of anti-IL-17 (10 mg/mL) to CHB-
significantly. (C) Subgroup analyses were performed in CHB patients with normal ALT but differing virus loads (n=13). With elevated virus loads, Treg
frequency increased significantly whereas Th17 barely changed. (D) Subgroup analyses were performed in CHB patients with similar inflammation
grades (G2–3) but with differing stages of fibrosis (n=56). With elevated fibrosis stages, Treg frequency decreased significantly whereas Th17
increased significantly. Data in subfigures B–D are presented as each value and the mean value. **, p,0.01; ***, p,0.001; NS, not significant.
doi:10.1371/journal.pone.0039307.g002
Figure 3. Peripheral Treg/Th17 ratios indicated liver injury and fibrosis progression of HBV-LF. A) There is a significant correlation
between peripheral Treg and Th17 frequencies in CHB patients. (n, case number; r, correlation coefficient; p value is shown). (B–D) Compared to HC
subjects, peripheral Treg/Th17 ratio dramatically increased in CHB patients, however it dramatically decreased with enhanced inflammation grades
(B) or elevated ALT levels (C) or advanced fibrosis stages (D). Data in subfigures B–D are presented as each value and the mean value. *, p,0.05; ***,
p,0.001.
doi:10.1371/journal.pone.0039307.g003
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+CD25
2 cells, for 6 days, and determined a-SMA proteins
in adherent HSCs by western blot. As we expected, compared to
HC-CD4
+CD25
2 cells, CHB-CD4
+CD25
2 cells could dramat-
ically up-regulated a-SMA proteins in HSCs, and anti-IL-17
antibody could dramatically weaken this up-regulation effect
(Figure 6C). The exact effect of IL-17 cytokine on activation of
HSCs was further proved by the incubation of HSCs with
recombinant IL-17 (1, 3, 5 ng/mL) for 6 days. And we observed
IL-17 significantly up-regulated a-SMA proteins of HSCs in
a dose-dependent manner (Figure 6D). To detect influence of
Treg response on HSCs, we firstly cultured CD4
+CD25
+ cells
(1610
4/well) from CHB patients with HSCs in both contact and
non-contact manners for 6 days. Data showed that CD4
+CD25
+
cells could only inhibit proliferation of HSCs in contact co-
cultures (Figure 6E). Besides, we determine the inhibition of
allogenic CD4
+CD25
+ cells from CHB patients on HSCs by
directly adding 10% (11,000/well), 20% (25,000/well), or 30%
(43,000/well) CD4
+CD25
+ cells to HSCs (1610
5/well) and co-
culturing them in contact manner for 6 days., and demonstrated
CD4
+CD25
+ cells dramatically inhibited cell proliferation and
PDGF-BB and TGF-b production of HSCs both in dose-
dependent manners (Figure 6F&G). Moreover, we respectively
co-cultured HSCs (1610
5/well) with CD4
+CD25
+ cells (1610
4/
well) from age-and-sex matched HC and CHB subjects (n=6) for
6 days and detected a-SMA proteins in HSCs at the end of co-
cultures, and found that CHB-CD4
+CD25
+ cells significantly
inhibited the expression of a-SMA proteins by HSCs in
comparison with HC-CD4
+CD25
+ cells (Figure 6H).
Figure 4. Treg cells regulated Th17 response in HBV-LF. (A) Compared to HC subjects (n=30), Th17-associated cytokines such as IL-17, IL-21
and IL-22 significantly increased in serum of CHB patients (n=77), however Treg-associated inhibitory cytokines IL-10 and TGF-b are similar in HC
subjects and CHB patients. (B) After 1 mg/mL HBcAg stimulation for 5 days, CD4
+ cells from CHB patients (n=6) showed a significantly enhanced
ability to secrete Th17-associated cytokines, including IL-17, IL-21, IL-22 and TNF-a, than do those from age-and-sex matched HC subjects (n=6). (C)
CD4
+CD25
+ cells from CHB patients (n=6) were co-cultured with HLA-identical CD4
+CD25
2 cells in both contact and non-contact manners for 5 days.
CD4
+CD25
+ cells significantly inhibited IL-17 and IL-22 production by CD4
+CD25
2 cells only in cell-contact manner. *, p,0.05 when compared to
medium only group;
#, p,0.05 when compared to uncontact co-culture group. (D) CD4
+CD25
+ cells from CHB patients (n=6) significantly inhibited
IL-17 and IL-22 production by CD4
+CD25
2 cells in a dose-dependent manner (p,0.05). No dramatic changes of IL-21 or TNF-a were observed after
co-cultures with CD4
+CD25
+ cells. Each line represents a cytokine (p.0.05). (E) CD4
+CD25
+ cells from CHB patients (n=6) inhibited proliferation of
HLA-identical CD4
+CD25
2 cells in a dose-dependent manner. Each line represents a CHB patient. (F) On the left panel, HLA-identical CD4
+CD25
+ cells
showed the greatest power to inhibit proliferation of CD4
+CD25
2 cells compared to allogenic CD4
+CD25
+ cells whether from other CHB patients or
age-and-sex matched HC subjects (n=6). On the right panel, the number of Foxp3
+ cells among different groups of CD4
+CD25
+ cells used to co-
culture with CD4
+CD25
2 cells was clarified. Data in subfigures A, B, C, and E are expressed as the mean 6 SEM. *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0039307.g004
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The above data from CHB patients demonstrated that both
Treg and Th17 responses were significantly correlated with liver
injury and fibrosis degree of HBV-LF, and differently regulated
cell proliferation and activation of HSCs, suggesting the Treg/
Th17 balance as an uncharacterized mechanism to regulate HBV-
LF progression. To gain in vivo evidence of the Treg/Th17 balance
during fibrosis progression, in this part we firstly established
ConA-induced mouse liver fibrosis models (Figure7A) and found
the frequencies of CD25
+ and IL-17
+ cells significantly increased
in livers and spleens after ConA administrations (Figure 7B–D),
which was similar with the increase of Treg and Th17 frequencies
in CHB patients. Then we depleted CD25
+ or IL-17
+ cells by
administering anti-CD25 mAb or anti-IL-17 mAb twice a week
(one day before and after ConA administration) in mouse models
Figure 5. CD4
+ cells during HBV-LF promoted activation and proliferation of primary HSCs. (A) Co-cultures between HSCs and CD4
+ cells
were monitored by a Cell-IQH system: HSCs were marked as blue dots and CD4
+ cells as green ones. (B) Growth curves of HSCs cultured alone or with
CD4
+ cells from age-and-sex matched HC and CHB subjects for 128 consecutive hours (n=6). (C) The concentrations of TGF-b, PDGF-BB, CTGF and
EGF in the supernatant at day 6 after co-cultures between HSCs and CD4
+ cells from age-and-sex matched HC and CHB subjects (n=6). (D) The a-SMA
proteins in HSCs that were contactly co-cultured with CD4
+ cells from age-and-sex matched HC and CHB subjects (n=6) were analyzed by western
blot and the relative quantification was also shown. Data in subfigures C and D are expressed as the mean 6 SEM. *, p,0.05 compared to medium
only group;
#, p,0.05 compared to the HC-CD4 group; ***, p,0.001.
doi:10.1371/journal.pone.0039307.g005
Figure 6. Treg and Th17 responses during HBV-LF differently regulated primary HSCs in vitro. (A) IL-17 blocking dramatically inhibited
the proliferation of HSCs, and re-addition of recombinant IL-17 enhanced HSCs proliferation in a dose-dependent manner (n=6). Each line represents
a CHB patient. (B) Recombinant IL-17 promoted PDGF-BB production by HSCs (n=6). Each line represents a growth factor. (C) The a-SMA proteins in
HSCs after co-cultures with CD4
+CD25
2 cells from age-and-sex matched HC and CHB subjects at day six determined by western blot, with or without
IL-17 blocking, are presented and the relative quantification is shown (n=6). (D) The a-SMA proteins in HSCs after IL-17 incubation at different
concentrations for six days determined by western blot are presented in the right panel and the relative quantification is in the left panel (n=3). (E)
CD4
+CD25
+ cells inhibit the proliferation of HSCs in cell contact manner (n=3). Data are expressed as the mean 6 SEM. (F) CD4
+CD25
+ cells from CHB
patients inhibited cell proliferation of HSCs in a dose-dependent manner (n=6). Each line represents a CHB patient. (G) CD4
+CD25
+ cells from CHB
patients inhibited PDGF-BB and TGF-b production of HSCs in dose-dependent manners (n=6). Each line represents a growth factor. (H) The a-SMA
proteins in HSCs after co-cultures with CD4
+CD25
+ cells from age-and-sex matched HC and CHB subjects at day six are presented and the relative
quantification is shown (n=6). Data in subfigures C, D, E&H are expressed as the mean 6 SEM *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0039307.g006
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frequencies of CD25
+ or IL-17
+ cell in livers and spleens using flow
cytometry one day after the second mAb administration, and the
frequencies of both cell types in mouse livers and spleens showed
dramatic decreases after mAb injections (Figure 7B–D). We also
measured serum ALT levels and found that ConA injection
enhanced ALT activity. The administration of anti-CD25 mAb
further increased whereas that of anti-IL-17 mAb decreased ALT
levels (Figure 7E). We moreover performed histopathological
analyses with Masson staining at week 4 after ConA injections and
found that, compared to the isotype-and-ConA treated mice, the
anti-CD25-and-ConA treated mice had intensified liver fibrosis
whereas anti-IL-17-and-ConA treated mice showed alleviated liver
fibrosis (Figure 7F). We further confirmed these results by
detecting the pro-fibrotic genes such as a-SMA, PDGF-BB,
TGF-b1, collagen type I and III, and observed that, both
significantly, anti-CD25-and-ConA treated mice up-regulated
whereas anti-IL-17-and-ConA treated mice down-regulated the
above genes in liver tissues (Figure 7G).
Discussion
Although increasing evidence suggests that inappropriate in-
flammation drives progression of fibrosis, cellular interactions
between inflammation and fibrosis in HBV-LF are poorly
understood [20]. Recently, much attention has focused on
imbalance between Treg cells and other effector T cells as
a mechanism of inappropriate inflammation [7–8,10–14]. Both
Treg and Th17 responses have been described in CHB patients
[4–6,9–10,14], however the significance of the Treg/Th17
balance during fibrosis progression of HBV-LF has not been
determined.
First, we performed several phenotype studies on peripheral
Treg and Th17 cells in CHB patients and found that Treg cells
from CHB patients expressed more CTLA4 but produced very
limited IL-10 and TGF-b1. Although we did not determine GITR
expression by Treg cells in our study, our data had already
demonstrated the inhibitory ability of these cells was not de-
pendent on cytokines, for Treg-associated cytokines (IL-10 and
TGF-b) were barely detected whether in CD4
+CD25
+Foxp3
+ cells
intracellularly after PMA/ionomycin stimulation, or in serum
samples, or in the supernatant of cultured-CD4
+ cells after HBcAg
incubation, and moreover, CD4
+CD25
+ cells from CHB patients
could only inhibit IL-17 and IL-22 production of CD4
+CD25
2
cells in contact co-cultures. In addition, the considerable co-
expression of CCR6 on peripheral Th17 cells in CHB patients
suggested the involvement of CCR6-CCL20 (CCR6 ligand)
pathway in CHB pathogenesis. Moreover, we also documented
a significantly higher frequency of peripheral CD4
+Foxp3
+IL-17
+
cells in CHB patients. Because CD4
+Foxp3
+IL-17
+ cells may exist
as a stable population with shared functions of both Treg and
Th17 cells, or as a transient population that may eventually
generate either Treg or Th17 cells, which had also been reported
by other researchers [4,7,9], these cells present a potential
mechanism to regulate the Treg/Th17 balance during HBV-LF.
However, future researches need to fully elucidate all these
mechanisms.
In the present study, we observed that both Treg and Th17
frequencies in the periphery of CHB patients were much higher
than those of HC subjects, which coincides with other researches
[4–6,9–10,14] and further supports the involvement of Treg and
Th17 cells in CHB pathogenesis. To further investigate effects of
Treg and Th17 responses in HBV-LF, we rigorously classified
CHB patients with certain clinical parameters into subgroups
according to their ALT levels, HBV loads and fibrosis degrees. In
the periphery of CHB patients, we found Treg frequency positively
correlated with HBV load whereas negatively correlated with liver
injury and fibrosis degree. In contrast, we observed a significantly
positive correlation of Th17 frequency with liver injury and
fibrosis degree of CHB patients, but no significant correlation
between Th17 frequency and HBV load was detected.
In CHB patients, although Treg cells could favor HBV
replication, they might be a protective factor of HBV-LF for: 1)
they could down-regulate inflammation to alleviate liver injury
and 2) they could inhibit the activation and proliferation of HSCs,
the cornerstone of liver fibrosis, during in-vitro co-cultures. The
exact significance of Treg cells in HBV infection might depend on
their presenting time: if they are aroused by HBV antigens in early
stage of virus infection, they might protect HBV thus being
‘‘harmful’’, however if they are induced by hosts in late phase of
virus infection to limit excessive inflammation, they might prevent
liver injury thus being ‘‘helpful’’. The existence of various subsets
of Treg cells with different functions could explain the double role
they play, which have been reported in several researches [2,6–8].
Since we only included CHB patients in this study, we could
dissect the presenting time of these Treg cells. Future studies
should undertake lineage-based studies of Treg cells at different
time points of HBV-LF.
On the effects of Th17 cells on CHB pathogenesis, we supposed
they might be a progressive factor of HBV-LF since we observed
a significantly correlation of Th17 frequency with liver injury and
fibrosis degree, no significant correlation between Th17 frequency
and HBV load, and moreover, IL-17 cytokines mainly produced
by Th17 cells could dramatically promote the activation and
proliferation of HSCs, the cornerstone of liver fibrosis. However,
HBV-specific Th17 cells had also been reported to play a role in
HBV clearance [10]. The data inconsistency might result from
different inclusion criteria of CHB patients in different studies,
thus the significance of Th17 cells in HBV-LF need to be
determined in the future.
In CHB patients, we firstly found a significant correlation
between Treg and Th17 frequencies in CHB patients, indicating
the close link of Treg and Th17 cells in CHB pathogenesis. We
therefore calculated the Treg/Th17 ratios in CHB patients, an
indicator of the balance between Treg and Th17 cells [10,12–14],
and presented it as an indicator of inflammation degree in this
process for 1) Treg and Th17 cells are both involved in CHB
pathogenesis and respectively known to down-regulate and up-
regulate the inflammation; and 2) the Treg/Th17 ratio are
negatively correlated with the inflammation degree of CHB
patients. This ratio is significantly higher in CHB patients
compared to HC subjects, which means anti-inflammation
overrides pro-inflammation in CHB pathogenesis, suggesting the
immune-tolerant state is required to sustain chronic HBV
infection. However, when liver fibrosis progresses in CHB patients,
this ratio dramatically decreased, indicating the persistent and
progressive inflammation is essential for fibrosis progression. All
these indicated the Treg/Th17 balance as an uncharacterized
mechanism to regulate HBV-LF progression.
We also analyzed lineage-associated cytokines of Treg and
Th17 cells [2,7–9] in serum of CHB patients, and found that
Th17-associated pro-inflammatory cytokines (IL-17, IL-22, IL-21
and TNF-a) were enriched whereas Treg-associated anti-in-
flammatory cytokines (IL-10 and TGF-b) were barely detected.
Moreover, in response to HBcAg, CD4
+CD25
2 cells from CHB
patients showed an enhanced ability to produce IL-17, IL-22, IL-
21 or TNF-a rather than IL-10 or TGF-b, whereas CD4
+CD25
+
cells barely produced these cytokines (data not shown), so
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e39307Figure 7. Treg/Th17 balance regulated liver fibrosis progression in mouse models. (A) Experimental protocol: Mice were i.v. injected with
ConA weekly for up to four weeks to establish liver fibrosis models. Depletion of CD25
+ or IL-17
+ cells during fibrosis progression was performed with
i.p. injection of either anti-CD25 or anti-IL-17 mAb one day before and after ConA injection twice a week. (B) Representative dot plots of CD4
+CD25
+
or CD4
+IL-17
+ cells in mouse livers are shown at week 4 after the administration of anti-CD25 or anti-IL-17 or isotype control mAb. (C) The frequencies
of CD4
+CD25
+ cells in mouse livers and spleens with administration of anti-CD25 or isotype control mAb were determined at week 0, 1, 2, 3 and 4
after ConA injection. ***, p,0.001 compared to isotype at week 0. (D) The frequencies of CD4
+IL-17
+ cells in mouse livers and spleens with
administration of anti-IL-17 or isotype control mAb were determined at week 0, 1, 2, 3 and 4 after ConA injection. **, p,0.01; ***, p,0.001 compared
to isotype at week 0. (E) Serum ALT levels at week 0, 1, 2, 3 and 4 after ConA injection. (F) Representative Masson staining of livers in ConA or PBS
treated mice is shown at week 4 after the administration of anti-CD25 or anti-IL-17 or isotype Ab (6100 and6200 magnification). n=6–8 per group.
(G) The mRNA levels of a-SMA, PDGF-BB, TGF-b, collagen type I and III in mouse livers at week 4 after ConA injection are shown in four groups:
isotype, isotype + ConA, anti-CD25+ ConA and anti-IL-17+ ConA groups. Data are expressed as the mean 6 SEM; *, p,0.05; **, p,0.01; ***, p,0.001.
doi:10.1371/journal.pone.0039307.g007
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+CD25
2 cells are supposed to contain almost all HBV-
specific Th17 cells. These results also indicated the cytokine-
independence of Treg cells and the cytokine-dependence of Th17
cells in CHB pathogenesis. Moreover, CD4
+CD25
+ cells could
dramatically inhibit cytokine production and proliferation of
HLA-identical CD4
+CD25
2 cells in a dose-dependent manner
but only during contact co-cultures, indicating the requirement of
cell contacts in Treg response. This part of research suggested the
existence of Treg/Th17 balance from the functional connections
that Treg cells could down-regulate Th17 response in vitro.
However, further in vivo evidence should be obtained. Interestingly,
with almost the same number of Foxp3
+ cells, HLA-identical
CD4
+CD25
+ cells rather than allogenic CD4
+CD25
+ cells aroused
the strongest inhibition on proliferation of CD4
+CD25
2 cells in
response to HBcAg, indicating the functional diversity of these
CD4
+CD25
+ cells for the following possible mechanisms: 1) Treg
response in HC subjects was not shaped by HBV-related antigens
thus been different from that in CHB patients; 2) HBV-related
antigens induced exclusive Treg response in each CHB individual
for the existence of various modes of host-virus interactions. So,
the ideal immune therapy for CHB patients should be based on
individualization.
Over the past decade, the activation of HSCs into myofibro-
blasts has always been critical to liver fibrogenesis [15]. We
therefore designed a series of co-cultures of different CD4
+ cell
lineages with HSCs to explore exact effects of different CD4
+ cell
responses on HSCs activation and proliferation. Total CD4
+ cells
include many functional lineages, including Th1, Th2, Treg, Th17
and even Th0 cells. Thus, data from CD4
+ cells reflect the effects
of complicated interactions among various lineages. From an
overall perspective, we demonstrated that total CD4
+ cells from
CHB patients dramatically promoted cell proliferation, a-SMA
expression and growth factors production (TGF-b, PDGF-BB,
CTGF and EGF) of HSCs, thus promoting liver fibrosis pro-
gression. Then CD4
+ cells were dissected into CD4
+CD25
+ and
CD4
+CD25
2 cells to perform respective co-cultures with HSCs,
and we observed absolutely opposite effects of these two CD4
+ cell
lineages on the activation of HSCs, for CD4
+CD25
+ cells inhibited
whereas CD4
+CD25
2 cells promoted a-SMA expression. In
addition, we found that during contact cultures, CD4
+CD25
+ cells
could inhibit cell proliferation and growth factors production of
HSCs in a dose-dependent manner. Moreover, the effect of IL-17
response induced by Th17 cells on HSCs was determined using
CD4
+CD25
2 cells in combination of anti-IL-17 antibody and
recombinant IL-17 cytokine, and we found that IL-17 neutrali-
zation down-regulated whereas IL-17 addition up-regulated both
cell proliferation and growth factors production of HSCs in
a significantly dose-dependent manner. These data again sug-
gested the Treg/Th17 imbalance as an uncharacterized mecha-
nism to regulate fibrosis progression, for Treg and Th17 responses
directly-regulate the pro-fibrotic features of HSCs in an adverse
manner, and also, Treg cells indirectly influence HSCs via
regulation of Th17 response.
To obtain in vivo evidence about effect of Treg/Th17 balance in
liver fibrosis, we established ConA-induced mouse liver fibrosis
models, characterized by the infiltration of abundant CD4
+ cells to
induce immune-mediated liver fibrosis. We found that the
frequencies of CD4
+CD25
+ and CD4
+IL-17
+ cells significantly
increased in mouse livers and spleens after ConA administration,
suggesting the involvement of Treg and Th17 responses in ConA-
induced liver fibrosis. This finding provides a premise to
investigate effect of the Treg/Th17 balance in fibrosis models
via depletion of CD25
+ or IL-17
+ cells. We also observed that, in
mouse livers, the peak of CD4
+ IL-17
+ cell frequency occurred at
week 1, which was earlier than appearing time of the peak of ALT
level and CD4
+CD25
+ cell frequency (both at week 2). Based on
what has already been established about CD4
+CD25
+ and CD4
+
IL-17
+ cells in mice [28–31], this phenomenon can be easily
explained as follows: ConA injection induces an increase in CD4
+
IL-17
+ cells, which cause severe liver injury, which in turn induces
CD4
+CD25
+ cells to constrain the Th17 response or directly
alleviate cell injury. From the perspective of liver injury, it is easy
to understand the resulting histopathology that the depletion of
CD25
+ cells promoted whereas the depletion of IL-17
+ cells
inhibited fibrosis progression. The protective role of CD4
+CD25
+
cells and the progressive role of CD4
+ IL-17
+ cells during liver
fibrosis were then demonstrated by mRNA levels of the pro-
fibrotic genes (a-SMA, TGF-b1, PDGF-BB, collagen I/III) in liver
tissues, for the depletion of CD25
+ cells up-regulated, whereas the
depletion of IL-17
+ cells down-regulated these genes. Thus, we
conclude that the Treg/Th17 balance regulates disease pro-
gression in ConA-induced fibrosis models.
Collectively, anti-inflammatory Treg cells and pro-inflammato-
ry Th17 cells have antagonistic effects on fibrosis progression in
HBV-LF for their influence on liver injury and HSCs function.
Here, we do not find a direct association between HBV replication
and fibrosis progression, but highlight immune-mediated liver
injury during HBV-LF progression. The characterization of the
Treg/Th17 balance in HBV-LF by our work paves the way for
future researches about inflammation and fibrosis pathways.
Supporting Information
Figure S1 Purification of CD4
+, CD4
+CD25
2 and
CD4
+CD25
+ cells. The purity of isolated CD4
+, CD4
+CD25
+
and CD4
+CD25
2 cells was confirmed .90% by flow cytometry.
(TIF)
Figure S2 Identification of isolated primary human
HSCs. The purity of isolated HSCs was determined as ranged
from 90% to 95% by GFAP staining. At day 7 after in vitro culture,
HSCs become activated and begin to express a-SMA.
(TIF)
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